A 94% twelve-month overall survival rate in newly diagnosed NPM1-mutant AML is the kind of number that makes a registrational trial feel less like a gamble and more like a formality. That is the signal buried inside the updated KOMET-007 data Kura Oncology and Kyowa Kirin presented at the European Hematology Association Congress this week, and it deserves more attention than the headline remission figures alone.
The KOMET-007 single-arm trial enrolled patients with NPM1-mutant or KMT2A-rearranged newly diagnosed AML and added ziftomenib at 600 mg once daily to standard 7+3 induction chemotherapy. Among 49 NPM1-mutant patients, composite remission (CRc) hit 96% and median OS remains unreached at 17.6 months of follow-up. The KMT2A-rearranged cohort, with shorter follow-up of 11 months, posted a 90% CRc and a 71% twelve-month OS rate. For context, historical 7+3 benchmarks show CR rates around 75% in younger fit patients and meaningfully lower survival at twelve months in older populations. The gap between those benchmarks and what KOMET-007 is generating is not trivial. Perhaps more clinically consequential: local MRD negativity among NPM1-mutant CRc responders reached 85%, and central NGS-based MRD negativity at the more stringent 0.01% threshold came in at 56%, with every MRD-negative patient achieving that clearance by Cycle 2.
Safety data at this duration of follow-up matter enormously for a combination that stacks a menin inhibitor on top of intensive chemotherapy. No Grade 4 differentiation syndrome appeared, Grade 3 differentiation syndrome occurred in only 4% of patients and resolved in all cases, and ziftomenib did not delay neutrophil or platelet recovery. The 60-day mortality rate among NPM1-mutant patients was 2%, a figure that compares favorably to published 7+3 early mortality data. Ziftomenib received FDA approval in November 2025 as monotherapy for relapsed or refractory NPM1-mutant AML, and the frontline combination use remains investigational pending the Phase 3 KOMET-017 readout. The tolerability seen in KOMET-007 removes one of the more credible objections to layering a targeted agent onto 7+3.
The single number to track from here is the KOMET-017 MRD negativity rate. If the registrational trial replicates the depth of molecular clearance seen in KOMET-007, specifically that 79% central MRD negativity at the 0.1% threshold, it will harden the argument that some NPM1-mutant patients can forgo allogeneic transplant entirely, and that outcome reshapes the post-induction treatment decision in a way that survival curves alone cannot.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
